Literature DB >> 9399745

Empiric trial of high-dose omeprazole in patients with posterior laryngitis: a prospective study.

J M Wo1, W J Grist, G Gussack, J M Delgaudio, J P Waring.   

Abstract

UNLABELLED: The optimal management of patients suspected with gastroesophageal reflux-related posterior laryngitis is unclear. History, physical examination, and ambulatory pH monitoring all have significant limitations in identifying patients who will respond to antireflux therapy.
OBJECTIVE: To evaluate the merit of empiric omeprazole therapy in patients with posterior laryngitis.
METHODS: Twenty-two patients (11 men/11 women, median age 58 yr) with newly diagnosed posterior laryngitis were enrolled. All had persistent laryngeal symptoms for at least 1 month. An empiric trial of omeprazole at 40 mg q.h.s. was given for 8 wk. Four laryngeal symptoms (hoarseness, throat burning/pain, throat clearing, and cough) and four esophageal symptoms (heartburn, regurgitation, dysphagia, and odynophagia) were scored from 0 to 3. Symptom scores were obtained before, 4 wk after, and 8 wk after the start of omeprazole. Patients were classified as responders if they were symptom free or satisfied with results. Omeprazole was stopped in the responders to look for relapse. Ambulatory pH monitoring was performed in patients who did not respond.
RESULTS: One patient discontinued omeprazole and withdrew from the study. In the remaining 21 patients, the total laryngeal and esophageal symptom scores significantly improved after empiric omeprazole. Fourteen patients (67%) were classified as responders. Eight patients (38%) had a relapse when omeprazole was stopped. Six patients (29%), interestingly, did not relapse and did not require long-term antireflux therapy. Seven patients (33%) were classified as nonresponders. Ambulatory pH monitoring was abnormal in four of the five patients who agreed to have this test. Increasing the dose of omeprazole to 40 mg b.i.d. provided no additional benefit in the nonresponders.
CONCLUSIONS: Empiric omeprazole therapy is a reasonable, initial approach to patients with suspected gastroesophageal reflux-related posterior laryngitis. A significant number of patients do well with a short course of antireflux therapy. Additionally, a third of the patients may not completely respond to intensive medical therapy despite the fact that reflux is documented.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9399745

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  23 in total

Review 1.  Atypical manifestations of gastroesophageal reflux disease.

Authors:  Michael F Vaezi
Journal:  MedGenMed       Date:  2005-10-27

2.  Prospective, observational study using rabeprazole in 455 patients with laryngopharyngeal reflux disease.

Authors:  Yoon Se Lee; Seung-Ho Choi; Young Ik Son; Young-Hak Park; Sang Yoon Kim; Soon Yuhl Nam
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-01-11       Impact factor: 2.503

Review 3.  Adult and paediatric GERD: diagnosis, phenotypes and avoidance of excess treatments.

Authors:  Kornilia Nikaki; Philip Woodland; Daniel Sifrim
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-07-27       Impact factor: 46.802

Review 4.  Supra-oesophageal manifestations of gastro-oesophageal reflux disease.

Authors:  Manuel Rodríguez-Téllez
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Extra-esophageal manifestations of gastroesophageal reflux disease: diagnosis and treatment.

Authors:  Christopher Hom; Michael F Vaezi
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

Review 6.  Diagnosis and management of supra-esophageal complications of reflux disease.

Authors:  T T Nostrant; J C Rabine
Journal:  Curr Gastroenterol Rep       Date:  2000-06

7.  The integrity and barrier function of porcine vocal fold epithelium: its susceptibility to damage by deoxycholic acid compared with pepsin.

Authors:  Zhewei Lou; Ting Gong; Chi Zhang; Matthew Silverman; Xiaxia Li; Zhihong Lin; Jack J Jiang
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-07-22       Impact factor: 2.503

8.  Is the proton pump inhibitor test helpful in patients with laryngeal symptoms?

Authors:  Jeong Hwan Kim; In-Kyung Sung; Sung Noh Hong; Sun-Young Lee; Hyung Seok Park; Chan Sup Shim
Journal:  Dig Dis Sci       Date:  2013-02-27       Impact factor: 3.199

Review 9.  Laryngeal manifestations of gastroesophageal reflux disease.

Authors:  Michael F Vaezi
Journal:  Curr Gastroenterol Rep       Date:  2008-06

Review 10.  The role of proton pump inhibitors in gastro-oesophageal reflux disease.

Authors:  Roy Dekel; Chad Morse; Ronnie Fass
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.